Daniel Morgensztern, MD
Enriched profileProfessor of Medicine; Director of Thoracic Oncology · Washington University School of Medicine in St. Louis
Daniel Morgensztern is Professor of Medicine; Director of Thoracic Oncology at Washington University School of Medicine in St. Louis. OpenAlex indexes 441 publications with 20,798 citations (h-index 50); ClinicalTrials.gov lists 16 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Daniel Morgensztern, MD, is Professor of Medicine at Washington University School of Medicine in St. Louis, Division of Oncology (Siteman Cancer Center). The public record shows 441 publications with 20,798 citations (h-index 50), centered on Lung Cancer (NSCLC/SCLC). It also documents an investigator role on 16 registered clinical trials, industry payments reported by 11 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Industry payments
Updated 27 Aug 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20256 payments
- Eli Lilly and CompanyProgram year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.1%PD-1 inhibitor44%Pembrolizumab100%Part B, office-administered≥11 patientsNucleoside Metabolic Inhibitor2.6%Fluorouracil100%Part B, office-administered≥12 patientsMetabolism & gastrointestinal
35.6%Other antiemetics29%Fosaprepitant100%Part B, office-administered≥12 patientsSerotonin-3 Receptor Antagonist3.8%Palonosetron hcl79%Ondansetron Hcl21%Part D + Part B≥63 patientsSensory organs
8.1%Corticosteroid8.1%Dexamethasone sodium phosphate76%Dexamethasone24%Part D + Part B≥78 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
Clinical cancer research
Article2026 - Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Journal of clinical oncology
Article2026 - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/daniel-morgensztern-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/daniel-morgensztern-b1337678
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
oncology.wustl.edu/people/daniel-morgensztern-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Mentions by others
where others cite or feature them- Other
medicine.yale.edu/news-article/daniel-morgensztern-md-joins-yale-cancer-center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗ - X / Twitter
x.com/washuoncology
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- Board Certified
American Board of Internal Medicine (Internal Medicine and Medical Oncology)
- Combined Internal Medicine/Hematology residency
State University of Rio de Janeiro; Internal Medicine internship and residency, University of Miami; Hematology-Oncology fellowship, University of Miami
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma.net ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma.net ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Secondary affiliations
appointments beyond the home institutionMedia & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungcancerstoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ramaswamy Govindan, MD
Washington University School of Medicine in St. Louis
Marin Kollef, MD
Washington University School of Medicine in St. Louis
Mark Huffman, MD
Washington University School of Medicine in St. Louis
Brad Kahl, MD
Washington University School of Medicine in St. Louis